Targeting glutamate signalling in depression: progress and prospects (Q38743867)

6 September 2017

title

Targeting glutamate signalling in depression: progress and prospects (English)

1 reference

6 September 2017

Chadi G Abdallah

2

0 references

author name string

James W Murrough

series ordinal

1

1 reference

6 September 2017

Sanjay J Mathew

series ordinal

3

1 reference

6 September 2017

language of work or name

1 reference

17 March 2017

1 reference

Nature Reviews Drug Discovery

6 September 2017

published in

1 reference

6 September 2017

volume

16

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

472-486

1 reference

Grand challenges in global mental health

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Glycine transporter-I inhibitors: a new class of antidepressant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Synaptic dysfunction in depression: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Organization, control and function of extrasynaptic NMDA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A neurotrophic model for stress-related mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

The molecular neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

NMDA Antagonist Neurotoxicity: Mechanism and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Sex differences in glutamate receptor gene expression in major depression and suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Glial reduction in the subgenual prefrontal cortex in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Fates-shifted is an F-box protein that targets Bicoid for degradation and regulates developmental fate determination in Drosophila embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Glutamate metabolism in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine: its mechanism(s) of action and unusual clinical uses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Serial infusions of low-dose ketamine for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Repeated S-ketamine infusions in therapy resistant depression: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A randomized controlled trial of intranasal ketamine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Oral ketamine for the treatment of pain and treatment-resistant depression†.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Activation of AMPA Receptors Mediates the Antidepressant Action of Deep Brain Stimulation of the Infralimbic Prefrontal Cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Synaptic plasticity: multiple forms, functions, and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Do the dissociative side effects of ketamine mediate its antidepressant effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Sleep homeostasis and cortical synchronization: I. Modeling the effects of synaptic strength on sleep slow waves

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Deuterated drugs draw heavier backing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Structure and dynamics of AMPA receptor GluA2 in resting, pre-open, and desensitized states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Challenges for and current status of research into positive modulators of AMPA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Predictive socioeconomic and clinical profiles of antidepressant response and remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

COGNITION-CHILDHOOD MALTREATMENT INTERACTIONS IN THE PREDICTION OF ANTIDEPRESSANT OUTCOMES IN MAJOR DEPRESSIVE DISORDER PATIENTS: RESULTS FROM THE iSPOT-D TRIAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Chronic ketamine administration modulates midbrain dopamine system in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

NMDA antagonist treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Altered thalamocortical rhythmicity and connectivity in mice lacking CaV3.1 T-type Ca2+ channels in unconsciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ionotropic and metabotropic glutamate receptor structure and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Rapid increase of an immediate early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Alterations in the N-methyl-d-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

In search of the mechanisms of ketamine’s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Ketamine Treatment and Global Brain Connectivity in Major Depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Cyloserine as an antidepressant agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.16

31 March 2020

Identifiers

DOI

10.1038/NRD.2017.16

1 reference

6 September 2017

1 reference